Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma
Protocol ID
N2012-01
Disease (Sub Disease)
Neuroblastoma
Diagnosis Stage
Relapse/ refractory
Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Sydney Children's Hospital Network
Sydney Children's Hospital Network
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 30 Years
International registry ID's
NCT02030964
| Study Title | NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma |
|---|---|
| Protocol ID | N2012-01 |
| Disease (Sub Disease) | Neuroblastoma |
| Diagnosis Stage | Relapse/ refractory |
| Sponsor | New Approaches to Neuroblastoma Therapy Consortium/ Sydney Children's Hospital Network |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02030964 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 01/12/2013 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 Years to 30 Years |
| International registry ID's | NCT02030964 |